Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 315, Issue 3, 2004, Pages 771-779

  Chun, Eunyoung ^a   Lee, Ki Young ^b  

^a Mogam Biotechnology Research Institute   (South Korea)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 1242272838     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.01.118     Document Type: Article

References (49)

1. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 48:1997;353-374.
2. Gan Y., Wientjes M.G., Schuller D.E., Au J.L. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 56:1996;2086-2093.
3. Bhalla K., Ibrado A.M., Tourkina E., Tang C., Grant S., Bullock G., Huang Y., Ponnathpur V., Mahoney M.E. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 82:1993;3133-3140.
4. Bhalla K., Ibrado A.M., Tourkina E., Tang C., Mahoney M.E., Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia. 7:1993;563-568.
5. Yoo Y.D., Park J.K., Choi J.Y., Lee K.H., Kang Y.K., Kim C.S., Shin S.W., Kim Y.H., Kim J.S. CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells. Clin. Cancer Res. 12:1998;3063-3068.
6. Chang Y.F., Li L.L., Wu C.W., Liu T.Y., Lui W.T., P'eng F.K., Chi C.W. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer. 77:1996;14-18.
7. Yen W.C., Wientjes M.G., Au J.L. Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics. Pharm. Res. 13:1996;1305-1312.
8. Fallo F., Pilon C., Barzon L., Pistorello M., Pagotto U., Altavilla G., Boscaro M., Sonino N. Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. Chemotherapy. 44:1998;129-134.
9. Fallo F., Pilon C., Barzon L., Pistorello M., Pagotto U., Altavilla G., Boscaro M., Sonino N. Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line. Endocr. Res. 22:1996;709-715.
10. Haugland H.K., Nygaard S.J., Tysnes O.B. Combined effect of alkyl-lysophospholipid and vincristine on proliferation, migration and invasion in human glioma cell lines in vitro. Anticancer Res. 19:1999;149-156.
11. Terzis A.J., Thorsen F., Heese O., Visted T., Bjerkvig R., Dahl O., Arnold H., Gundersen G. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br. J. Cancer. 75:1997;1744-1752.
12. Siefker-Radtke A.O., Millikan R.E., Tu S.M., Moore D.F., Smith T.L. Jr., Williams D., Logothetis C.J. Phase III trial of fluorouracil, interferon Alfa-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J. Clin. Oncol. 20:2002;1361-1367.
13. Rodriguez E.M., Parra M.T., Rufas J.S., Suja J.A. Colchicine promotes a change in chromosome structure without loss of sister chromatid cohesion in prometaphase I-arrested bivalents. Chromosoma. 110:2001;478-486.
14. Nogales E., Wolf S.G., Downing K.H. Structure of the alpha beta tubulin dimer by electron crystallography. Nature. 391:1998;199-203.
15. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem. Pharmacol. 57:1999;1215-1221.
16. Milross C.G., Mason K.A., Hunter N.R., Chung W.K., Peters L.J., Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst. 88:1996;1308-1314.
17. Milas L., Hunter N.R., Kurdoglu B., Mason K.A., Meyn R.E., Stephens L.C., Peters L.J. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother. Pharmacol. 35:1995;297-303.
18. Wang T.H., Wang H.S., Soong Y.H. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 88:2000;2619-2628.
19. Cheng S.C., Luo D., Xie Y. Taxol induced Bcl-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line. Cell Biol. Int. 25:2001;261-265.
20. Wang H.T., Popp D.M., Wang H.S., Saitoh M., Mural J.G., Henley D.C., Ichijo H., Wimalasena J. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J. Biol. Chem. 274:1999;8208-8216.
21. Lin H.L., Chang Y.F., Liu T.Y., Wu C.W., Chi C.W. Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. AntiCancer Res. 18:1998;3443-3449.
22. Parekh H., Wiesen K., Simpkins H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem. Pharmacol. 53:1997;461-470.
23. Huang M., Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett. 135:1999;97-105.
24. Bates S.E., Zhan Z., Dickstein B., Lee J.S., Scala S., Fojo A.T., Paull K., Wilson W. Reversal of multidrug resistance. J. Hematother. 3:1994;219-223.
25. Luo D., Cheng S.C., Xie X., Xie Y. Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protein levels. Tumour Biol. 20:1999;331-340.
26. Huang Y., Ibrado A.M., Reed J.C., Bullock G., Ray S., Tang C., Bhalla K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 11:1997;253-257.
27. Jang S.H., Wientjes M.G., Au J.L. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J. Pharmacol. Exp. Ther. 298:2001;1236-1242.
28. Strobel T., Kraeft S.K., Chen L.B., Cannistra S.A. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res. 58:1998;4776-4781.
29. Kondratov R.V., Komarov P.G., Becker Y., Ewenson A., Gudkov A.V. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc. Natl. Acad. Sci. USA. 98:2001;14078-14083.
30. Kavallaris M., Kuo D.Y., Burkhart C.A., Regl D.L., Norris M.D., Haber M., Horwitz S.B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 100:1997;1282-1293.
31. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T., Fojo T., Poruchynsky M.S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272:1997;17118-17125.
32. Panvichian R., Orth K., Day M.L., Day K.C., Pilat M.J., Pienta K.J. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res. 58:1998;4667-4672.
33. Janicke R.U., Sprengart M.L., Wati M.R., Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273:1998;9357-9360.
34. Gazitt Y., Rothenberg M.L., Hilsenbeck S.G., Fey V., Thomas C., Montegomrey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int. J. Oncol. 13:1998;839-848.
35. Siegel D.S., Zhang X., Feinman R., Teitz T., Zelenetz A., Richon V.M., Rifkind R.A., Marks P.A., Haeli J. Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. Proc. Natl. Acad. Sci. USA. 95:1998;162-166.
36. Liu J.R., Fletcher B., Page C., Hu C., Nunez G., Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol. 70:1998;398-403.
37. Huang Y., Ray S., Reed J.C., Ibrado A.M., Tang C., Nawabi A., Bhalla K. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res. Treat. 42:1997;73-81.
38. Park J.G., Lee J.H., Kang M.S., Park K.J., Jeon Y.M., Lee H.J., Kwon H.S., Park H.S., Yeo K.S., Lee K.U.et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer. 62:1995;276-282.
39. Shin E.C., Shin J.S., Park J.H., Kim J.J., Kim H., Kim S.J. Expression of Fas-related genes in human hepatocellular carcinomas. Cancer Lett. 134:1998;155-162.
40. + T cells in xenografted nude mice. J. Immunol. 170:2003;1183-1190.
41. Woods C.M., Zhu J., McQueney P.A., Bollag D., Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med. 1:1995;506-526.
42. Vasey P.A., Jones N.A., Jenkins S., Dive C., Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol. Pharmacol. 50:1996;1536-1540.
43. Vikhanskaya F., Vignati S., Beccaglia P., Ottoboni C., Russo P., D'Incalci M., Broggini M. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp. Cell Res. 241:1998;96-101.
44. Powell S.N., DeFrank J.S., Connell P., Eogan M., Preffer F., Dombkowski D., Tang W., Friend S. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 55:1995;1643-1648.
45. Wahl A.F., Donaldson K.L., Fairchild C., Lee F.Y., Foster S.A., Demers G.W., Galloway D.A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2:1996;72-79.
46. Maheswaran S., Englert C., Bennett P., Heinrich G., Haber D.A. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 9:1995;2143-2156.
47. Murphy M., Hinman A., Levine A.J. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 10:1996;2971-2980.
48. Tang C., Willingham M.C., Reed J.C., Miyashita T., Ray S., Ponnathpur V., Huang Y., Mahoney M.E., Bullock G., Bhalla K. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia. 8:1994;1960-1969.
49. Chao Y., Chan W.K., Birkhofer M.J., Hu O.Y., Wang S.S., Huang Y.S., Liu M., Whang-Peng J., Chi K.H., Lui W.Y., Lee S.D. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br. J. Cancer. 78:1998;34-39.